List of Excipients in Branded Drug RIOMET

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sun Pharmaceutical Industries Inc	RIOMET	metformin hydrochloride	10631-238	GLYCERIN
Sun Pharmaceutical Industries Inc	RIOMET	metformin hydrochloride	10631-238	HYDROCHLORIC ACID
Sun Pharmaceutical Industries Inc	RIOMET	metformin hydrochloride	10631-238	POTASSIUM BICARBONATE
Sun Pharmaceutical Industries Inc	RIOMET	metformin hydrochloride	10631-238	PROPYLENE GLYCOL
Sun Pharmaceutical Industries Inc	RIOMET	metformin hydrochloride	10631-238	SUCRALOSE
Sun Pharmaceutical Industries Inc	RIOMET	metformin hydrochloride	10631-238	XYLITOL

Riomet Excipient Strategy and Commercial Opportunities for Metformin Oral Solution

Last updated: August 13, 2026

Riomet is an immediate-release metformin hydrochloride oral solution, generally supplied at 500 mg per 5 mL. Its commercial value comes from liquid dosing, sugar-free positioning, and use in patients who cannot swallow tablets. The product has limited apparent patent exclusivity, so future opportunities depend on excipient performance, device differentiation, manufacturing control, lifecycle management, and market access rather than conventional composition-of-matter protection.

What is Riomet and who manufactures it?

Riomet contains metformin hydrochloride, a biguanide antihyperglycemic agent used as an adjunct to diet and exercise for type 2 diabetes. The product is an oral solution rather than a tablet or capsule.

Attribute	Riomet profile
Active ingredient	Metformin hydrochloride
Dosage form	Immediate-release oral solution
Common strength	500 mg/5 mL
Drug class	Biguanide
Primary indication	Type 2 diabetes
Administration	Oral, measured liquid dose
Regulatory pathway	FDA-approved new drug application
Primary differentiation	Liquid delivery and sugar-free formulation
Main alternatives	Immediate-release tablets, extended-release tablets, generic metformin solutions
Patent value	Limited apparent remaining Orange Book value for the original product

Riomet is associated with NDA 020357 in FDA drug databases and product labeling. The product is commonly marketed by Sun Pharmaceutical Industries through its U.S. commercial operations, although ownership, distributor, and labeler information should be checked against the current FDA listing and package label before a transaction or litigation assessment.[1,2]

What excipients are used in Riomet?

The Riomet formulation is designed around aqueous solubility, palatability, chemical stability, dose uniformity, and microbial control. Public labeling identifies excipients including sweetening and flavoring agents, a preservative system, and pH-adjusting ingredients.[1]

The exact excipient system is commercially important because metformin has a strong bitter taste and the liquid format creates greater exposure to taste, microbial contamination, and dosing variability than a conventional tablet.

Core excipient functions

Formulation requirement	Excipient strategy	Commercial relevance
Metformin solubilization	Purified water and pH control	Supports a clear, uniform solution
Taste masking	Sweeteners and flavors	Improves adherence and repeat use
Microbial protection	Preservative system	Supports multidose packaging
Chemical stability	Buffer or pH adjustment	Controls degradation and preservative performance
Dose accuracy	Low-viscosity aqueous vehicle	Enables oral syringe or calibrated cup dosing
Patient acceptability	Sugar-free, alcohol-free presentation	Supports diabetes, pediatric, geriatric, and dysphagia markets
Packaging compatibility	HDPE or equivalent multidose container	Limits adsorption, leachables, and preservative loss

The formulation should not be treated as interchangeable with an extemporaneously compounded metformin liquid. A commercial product must demonstrate stability, microbiological quality, preservative effectiveness, extractables and leachables control, dosing accuracy, and container-closure integrity.

Which excipients create the largest commercial opportunities?

The highest-value opportunities are taste masking, preservative optimization, dosing accuracy, and improved stability after opening.

Taste masking and flavor systems

Metformin’s bitterness is a major barrier to oral-liquid adherence. A reformulation program could evaluate:

• High-intensity sweeteners such as sucralose, acesulfame potassium, or steviol glycosides.
• Polyol systems such as sorbitol or maltitol, subject to gastrointestinal tolerability.
• Flavor combinations that suppress bitterness rather than simply increasing sweetness.
• Ion-pairing or resin-based taste-masking systems.
• Cyclodextrin or polymeric complexation, if the approach does not impair dose release or create a new safety concern.
• Microencapsulation for taste suppression, provided the product remains an immediate-release solution or suspension with acceptable redispersibility.

A strong commercial formulation would reduce bitterness without adding sugar, ethanol, excessive viscosity, or a high gastrointestinal burden. A patentable claim could focus on a defined metformin-to-sweetener ratio, a pH range, a preservative combination, or a sensory performance threshold.

Preservative systems

A multidose oral solution requires control of bacterial, yeast, and mold growth during storage and repeated use. Potential systems include sodium benzoate, potassium sorbate, parabens, or combinations of preservatives. The selection depends on pH, preservative solubility, compatibility with flavors, and regional regulatory acceptance.

Preservative optimization can produce meaningful differentiation when it delivers:

• Longer in-use stability.
• Lower preservative concentration.
• Improved palatability.
• Reduced container interaction.
• Better performance across temperature excursions.
• Compatibility with pediatric and geriatric use.

A preservative change would normally require comparative stability and microbiological data. It may also alter the regulatory filing strategy if the change affects composition, manufacturing, specifications, or labeled storage conditions.

pH and buffer control

Metformin hydrochloride is highly water soluble. The principal technical challenge is not simple solubilization but maintaining stability, taste, preservative effectiveness, and packaging compatibility over shelf life.

A buffer system can influence:

• Metformin chemical stability.
• Preservative activity.
• Flavor perception.
• Container-closure interaction.
• Precipitation risk during temperature changes.
• Compatibility with enteral feeding equipment.

A formulation patent could claim a narrow pH range combined with a particular preservative and flavor system. The patent value would depend on whether the combination produces an unexpected stability, taste, or microbial benefit.

Viscosity modifiers

A modest increase in viscosity can reduce dosing splash and improve oral-syringe handling. Excessive viscosity creates problems with dose withdrawal, enteral-tube administration, cleaning, and residual drug loss.

Candidate materials include hydroxypropyl cellulose, hydroxyethyl cellulose, xanthan gum, and other pharmaceutical-grade polymers. Each raises technical issues:

• Incomplete withdrawal from the container.
• Dose nonuniformity at the end of bottle life.
• Interaction with preservatives.
• Syringe clogging.
• Delayed emptying from feeding tubes.
• Increased residue after administration.

Viscosity is therefore a device and human-factors opportunity rather than an automatic formulation improvement.

What formulation patents could protect a next-generation Riomet product?

The original Riomet product has limited apparent patent-based exclusivity. A new entrant would need to create a distinct formulation, device, manufacturing process, or clinical-use profile to establish defensible intellectual property.

Potential patent claim categories

Patent category	Example claim focus	Strength assessment
Composition	Metformin, sweetener, flavor, preservative, and pH combination	Moderate if unexpected performance is demonstrated
Taste masking	Defined complex, encapsulate, resin, or sensory threshold	Moderate to strong if technically difficult to reproduce
Stability	Composition retaining potency after extended in-use storage	Moderate
Packaging	Container and dosing system limiting adsorption or contamination	Moderate
Dosing device	Oral syringe or closure providing accurate 5 mL dosing	Low to moderate unless technically distinctive
Manufacturing	Mixing, filtration, filling, or preservation process	Moderate if it solves a scale-up or sterility problem
Method of use	Use in dysphagia, tube-fed, geriatric, or pediatric populations	Usually weaker without clinical support
Combination product	Metformin solution with monitoring, adherence, or dose-management technology	Potentially strong but commercially more complex

A formulation patent should avoid claiming only routine substitution of one flavor or sweetener for another. The strongest filing would connect the composition to measurable results, such as improved bitterness scores, preservative efficacy, long-term stability, reduced dosing residue, or improved administration through feeding tubes.

When does Riomet lose exclusivity?

Riomet’s original regulatory exclusivity and any early formulation patents are old. The commercial product should be analyzed as a mature, largely genericized medicine rather than as a product protected by a current composition-of-matter patent.

Exclusivity element	Riomet assessment
Active ingredient exclusivity	Expired
Original product exclusivity	Expired or no longer commercially material
Composition-of-matter patent	Not a current barrier
Orange Book patent barrier	No current barrier should be assumed without a live Orange Book verification
Generic competition	Established for metformin tablets; oral-solution competition is narrower
Biosimilar risk	Not applicable; metformin is a small molecule
Primary commercial barrier	Formulation know-how, approval cost, supply reliability, and channel access

FDA approval of a competing metformin oral solution would generally be assessed under the abbreviated new drug application framework if the reference product and dosage-form requirements were satisfied. The practical challenge is that oral solutions require more than active-ingredient equivalence. The applicant must establish pharmaceutical equivalence, product quality, labeling conformity, and relevant bioequivalence or comparative requirements.

What is the Orange Book status of Riomet?

The FDA Orange Book is the controlling source for listed patents, exclusivity, therapeutic equivalence codes, and reference-product designations.[3] Riomet should be reviewed by NDA number and active ingredient because product names, labelers, and marketing status can change.

For commercial planning, the key conclusions are:

1. Riomet is not protected by a live metformin composition patent.
2. The original product’s commercial position is not based on current NCE exclusivity.
3. A competing oral solution may face regulatory and technical hurdles even if it faces little patent risk.
4. A newly developed formulation may obtain separate patent protection if it has non-obvious composition or performance characteristics.
5. Orange Book-listed patents, if any, must be reviewed at the time of filing, launch, licensing, or Paragraph IV certification.

Which companies are challenging Riomet or developing alternatives?

The competitive field includes four groups:

• Manufacturers of generic immediate-release metformin tablets.
• Manufacturers of extended-release metformin tablets.
• Suppliers of metformin oral solutions or suspensions.
• Compounding pharmacies and specialty pharmacies preparing liquid metformin products.

The tablet market is highly competitive and price-driven. The liquid market is smaller because of formulation complexity, lower prescription volume, greater packaging requirements, and the need for patient-specific dosing support.

No biosimilar pathway applies. Metformin is a chemically synthesized small molecule, so competitive entry is governed by generic-drug and new-drug pathways rather than by biosimilar approval.

What generic entry risks exist for Riomet?

Generic entry risk is high at the active-ingredient level but more limited at the commercial oral-solution level.

High-risk areas

A competitor can likely challenge the product through:

• A conventional metformin oral solution.
• A different flavor system.
• A different preservative system.
• An alternative bottle and dosing device.
• A lower-cost manufacturing process.
• A pharmacy-distributed compounded product.

Entry barriers

The principal barriers are:

• Taste acceptance.
• Preservative efficacy.
• In-use stability.
• Dosing accuracy.
• Container-closure compatibility.
• Drug shortage and supply-chain requirements.
• Pediatric and geriatric usability.
• Pharmacy and payer reimbursement.

The strongest defense for a branded Riomet successor would be a combination of brand recognition, reliable supply, a superior dosing device, and a formulation patent tied to demonstrated patient-use benefits.

What licensing deals could support a Riomet lifecycle strategy?

Licensing opportunities are more likely to involve enabling technologies than the metformin molecule itself.

Potential targets include:

• Taste-masking platforms.
• Pediatric oral-liquid flavor systems.
• Low-preservative multidose technologies.
• Oral-syringe and bottle-closure systems.
• Tube-feeding compatibility technologies.
• Stability-enhancing packaging.
• Digital adherence systems linked to liquid dosing.
• Contract manufacturing capacity for pharmaceutical oral solutions.

A license should be evaluated against freedom-to-operate risk in the United States, Europe, Japan, and major emerging markets. A platform license may have greater value if it can be used across other bitter or highly soluble drugs, rather than only in metformin.

How does Riomet compare with metformin tablets?

Factor	Riomet oral solution	Immediate-release tablets
Swallowing burden	Low	Moderate to high
Dose flexibility	High	Limited by tablet strength
Taste risk	High	Minimal
Packaging complexity	High	Lower
Preservative requirement	Usually required for multidose liquid	Not usually required
Cost of goods	Higher	Lower
Pediatric and dysphagia utility	Stronger	Weaker
Generic substitution pressure	Moderate	Very high
Patent opportunity	Formulation and device	Limited for mature product
Adherence opportunity	Strong if palatable	Strong if swallowing is acceptable

Riomet is commercially attractive where the liquid format solves a real administration problem. It is less competitive for adults who can use low-cost tablets and do not require flexible dosing.

What FDA regulatory issues affect a new Riomet formulation?

A reformulated product may require a supplement, an ANDA, or a new NDA depending on the relationship to the reference product and the extent of the change. FDA review will focus on:

• Identity, strength, quality, purity, and potency.
• Assay and degradation products.
• Microbial limits.
• Preservative effectiveness.
• Stability in the marketed container.
• In-use stability after opening.
• Dose uniformity throughout bottle life.
• Extractables and leachables.
• Labeling and measuring-device performance.
• Compatibility with enteral feeding tubes if that use is promoted.

The product should use a calibrated oral syringe where dosing accuracy is important. A household teaspoon creates avoidable medication-error risk and is a weak commercial position.

What is the commercial opportunity for Riomet excipient innovation?

The most credible opportunity is a premium, differentiated metformin liquid that targets patients underserved by tablets:

1. Children and adolescents requiring flexible dosing.
2. Older adults with dysphagia.
3. Patients receiving enteral nutrition.
4. Patients with neurologic or psychiatric conditions affecting swallowing.
5. Care settings that need accurate liquid administration.
6. Patients who cannot tolerate the taste or excipients of existing products.
7. Markets where metformin liquid supply is inconsistent.

The opportunity is niche rather than mass-market. Commercial success would depend on reimbursement, pharmacy availability, institutional contracts, and evidence that the formulation improves persistence or administration accuracy.

Key Takeaways

• Riomet is an immediate-release metformin hydrochloride oral solution, commonly supplied at 500 mg/5 mL.
• Its principal value is liquid administration, not active-ingredient exclusivity.
• The highest-value excipient opportunities are taste masking, preservative optimization, pH control, in-use stability, and dosing accuracy.
• Metformin has no biosimilar risk because it is a small-molecule drug.
• Generic entry risk is high for metformin generally but narrower for a well-designed oral solution.
• A new Riomet formulation could obtain protection through composition, taste-masking, stability, packaging, manufacturing, or dosing-device patents.
• FDA Orange Book review should be performed by NDA and current labeler before any launch or litigation decision.
• The best commercial targets are dysphagia, pediatric, geriatric, enteral-feeding, and institutional-care segments.
• The strongest lifecycle strategy combines a differentiated excipient system with a calibrated dosing device and reliable supply.

FAQs About Riomet Excipient and Commercial Strategy

Is Riomet sugar-free?

Riomet is positioned as a sugar-free metformin oral solution. The precise sweetener and flavor system should be confirmed against the current FDA-approved labeling before formulation benchmarking.[1]

Can metformin oral solution be administered through an enteral feeding tube?

Administration may be technically feasible, but tube compatibility, dose recovery, adsorption, clogging, and flushing procedures require product-specific evaluation. A manufacturer should not promote tube administration without supporting data.

Is a metformin oral solution patentable?

Yes. The metformin molecule is old, but a non-obvious excipient combination, taste-masking system, packaging configuration, manufacturing process, or dosing device may support patent protection.

Why is metformin liquid less common than metformin tablets?

Liquid metformin has higher formulation, packaging, stability, palatability, and manufacturing costs. Most adults can use tablets, reducing the addressable market for oral solution products.

What is the strongest commercial differentiator for a Riomet competitor?

A combination of superior taste, accurate oral-syringe dosing, extended in-use stability, reliable supply, and reimbursement support is likely to be more valuable than a minor flavor change alone.

References

1. DailyMed. (n.d.). Riomet: Metformin hydrochloride oral solution prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

4. U.S. Food and Drug Administration. (2017). Dosage delivery devices for orally ingested OTC liquid drug products. https://www.fda.gov/

5. U.S. Pharmacopeia. (n.d.). General chapter <51>: Antimicrobial effectiveness testing. United States Pharmacopeial Convention.